Trial Profile

Phase II study of Zanidatamab Zovodotin

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanidatamab zovodotin (Primary)
Indications Cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Jan 2024 According to Zymeworks media release, the company plans to conduct a Phase 2 study in NSCLC in 2024.
13 Mar 2023 New trial record
07 Mar 2023 According to Zymeworks media release, the study has been progressed to phase II and the enrollment is expected to commence in 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com